Navigation Links
Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Date:6/6/2008

Collaboration Will Seek to Identify Unique microRNA Signatures That Will

Predict Risk of Recurrence in Lung Cancer Patients The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction and Quantification Technologies, and M. D. Anderson's Extensive Know-How

and Experience in Lung Cancer Research Test Will be Designed to Assist in Distinguishing Patients With High Risk of Recurrence, who may Benefit From Adjuvant or Targeted Therapies, From

Those With Low Risk

REHOVOT, Israel and JERSEY CITY, New Jersey, June 6 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.

Current treatment for lung cancer includes surgical resection which may be followed by adjuvant therapy. While patients with high risk of recurrence may benefit from adjuvant therapy, those with low risk of recurrence may be exposed to unnecessary toxicities. The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens.

"The potential diagnostic applications of microRNA biomarkers are broad and diverse," noted Amir Avniel, president and CEO of Rosetta Genomics. "We are very pleased to be collaborating with M. (space) D. Anderson, one of the world's leading cancer research centers, on this important project in lung cancer. We believe that the experience we have in working with microRNA biomarkers, combined with M. (space) D. Anderson's extensive experience in lung cancer research, makes this a strong colla
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
7. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
8. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
9. Fals-Stewart Earns Hazeldens 2007 Dan Anderson Research Award
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...ificance of AHCC for maintaining a healthy immune ...-- A recently published study in Nutrition and Ca...dical University in Osaka, Japan has shown that AH...mune function by increasing the number of dendriti...stem responsible for presenting foreign substances...
(Date:1/6/2009)...Mass., Jan. 6 Cequent Pharmaceutic...s to deliver RNAi-based treatments to prevent and ...s recently completed a successful toxicology study...tk RNAi therapeutic targeting the primary oncogene...us polyposis). FAP is an inherited gastrointestina...
(Date:1/5/2009)...A, Md., Jan. 5 Micromet,...any developing novel, proprietary,antibodies for ...ne diseases,provides an outlook on key events an...ntends to provide an update on its research and de... -- April 12 to 16, 2009: Update on several pre...
(Date:12/29/2008)...d., Dec. 29 The winner ... Protection was announced today by Dr. Peter G. Go...rovement Institute. , , The winner of the annu...rson Cancer Center -- for its best practice " IN...m provides for 1) enhanced human subjects protecti...
Breaking Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 52008 Human Research Protection Award Recipients Announced 2URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 1URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 2URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 3URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 4Protect Your Family From The Silent Killer This Winter 29321 1Protect Your Family From The Silent Killer This Winter 29321 2Protect Your Family From The Silent Killer This Winter 29321 3Study improves recovery for mothers with depression 29317 1Medicare coding for maggots and maggot therapy 5791 1Medicare coding for maggots and maggot therapy 5791 2Medicare coding for maggots and maggot therapy 5791 3
...May 02, 2007 /PRNewswire-FirstCall/ --,Genelabs Te...on was,made today at the 20th International Confer...ngs, California, on a,non-nucleoside hepatitis C v...labs. , The oral presentation was given by Christo...istry at Genelabs, entitled,"GL59728: A Potent All...
... WIRE)--May 4, 2007 - Argos Therapeutics,today ann...essive,properties of soluble CD83 at the 7th Joint...ncisco, May 5-9. The presentations,will be made in...f,Western Ontario., "These data suggest that solub...lantation, and that it can also act,synergisticall...
Other Medicine Technology:Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
(Date:1/8/2009)...Jude study could shape new treatments for secondar...ire-USNewswire/ -- Scientists at St. Jude Children...ctive treatment for bacterial pneumonia following ...ycin and azithromycin, which kill bacteria by inhi... than a standard first-line treatment with the "be...
(Date:1/8/2009)...red bad cholesterol more effectively than Zocor ,...fter nearly a year of review, U.S. health official...use of the controversial cholesterol-lowering drug...on said there was no significant difference in car...rin and patients taking the drug Zocor. , But, ...
(Date:1/8/2009)... Jan. 8 Hanger Orthopedi...e that throughout the fourth quarter of 2008 it ac..., Rocky Mountain Orthotic-Prosthetics Center, Ries...rst Coast Orthotics & Prosthetics, and Orthope...ns add patient care centers to existing markets in...
(Date:1/8/2009)...CO, Jan. 8 Medivation, I...Hung, M.D., president and chief,executive officer...thcare,Conference on Wednesday, January 14, at 10...otel in San Francisco. , Dr. Hung will prov...velopment programs for Dimebon for Alzheimer,s and...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
... expert, the way one sneezes or the sound that com...ualities of a person.// Patti A. Wood, an Atlanta-...r Benadryl, said a sneeze could offer a revealing ...ty, reported the online edition of ABC News. Wood...
... of the Irish Medical Organization (IMO) has expre...lection for Fine Gael// . Previously, Nora Owen, t... The ambitious contestant is seeking the nominatio... is positive about the success in the political pa...
...in grave consequences. People who are in their 60s...ise. This increases their physical function// and ...ead to a loss of functional independence in the co...r. Dennis T. Villareal from Washington University ...
... women aged 60 and younger have an increased susce...red to others. The results of the study are especi...sts of such patients when compared to heart attack... of the study have been published in the April 24 ...
Other Medicine News:Health News:Depression Accompanies Heart Attacks in Younger Women 2
Vannas Capsulotomy scissors angled
Gills-Vannas straight capsulotomy flat handle scissors
Vannas angled capsulotomy round handle scissors
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium.
Medicine Products: